ClinicalTrials.gg
RecruitingNCT07755410Updated Nov 18, 2026

A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)

A Phase 2 interventional study of ALKS 7290 and Placebo in Attention Deficit Disorder With Hyperactivity (ADHD), sponsored by Alkermes, Inc.. Recruiting at 28 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Alkermes, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 18, 202627 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Planned enrollment
77th of 706
312 · median 70
Started
2026
with 32 others
Phase 2
80 of 807
3 open now
Primary completion
2027-07
later than 60 of 115 live
Registered
797th of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 77th largest by planned enrollment of the 706 interventional ones that give a count, is one of 33 that started in 2026, is one of 80 in phase 2, reaches primary completion later than 60 of the 115 other live ones, and was the 797th registered.

Attention Deficit Disorder with Hyperactivity

1,818 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

92 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to measure safety and the improvement in symptoms in subjects with ADHD when taking ALKS 7290 tablets compared with placebo tablets.

03

Conditions studied

  • Attention Deficit Disorder With Hyperactivity (ADHD)

Keywords

  • ADHD
  • Attention Deficit Disorder with Hyperactivity
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets the -5 criteria for ADHD, as confirmed by the Mini-International Neuropsychiatric Interview (MINI) for ADHD Studies 7.0.2.
  • Is otherwise healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring. Participants must be stable on permitted medication for 2 months prior to first visit, without anticipated changes to dose.
  • AISRS total score of ≥26
  • CGI-S score ≥ 4 (moderately ill or worse)
  • Has a within 18 to 35 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Has a known history of intellectual developmental disorder or cognitive impairment that, in the opinion of the Investigator, would interfere with study participation.
  • Has any of the following psychiatric conditions per the criteria, as assessed by the MINI. Conditions not assessable by the MINI should be assessed by clinical judgement; Diagnosis of schizophrenia, schizoaffective disorder, or bipolar I or II disorder, or current, unstable, MDD or GAD.
  • cognitive difficulties including dementia, delirium or amnestic syndromes, or any other cognitive disorder present with the past 2 years that could interfere with participation in the study.
  • Moderate to severe substance use disorder according to DSM-5 guidelines, including use of alcohol, nicotine, cannabis, narcotics, or any illicit substance.
  • Any other psychiatric condition that could interfere with participation in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
312 participants (estimated)

Study arms

  • Experimental
    Dose Level 1

    Drug: ALKS 7290

  • Experimental
    Dose Level 2

    Drug: ALKS 7290

  • Experimental
    Dose Level 3

    Drug: ALKS 7290

  • Placebo comparator
    Placebo

    Placebo capsule taken daily

    Drug: Placebo

Interventions

  • DrugALKS 7290

    ALKS 7290 tablets taken daily, orally, for 4 weeks

  • DrugPlacebo

    Placebo capsule taken daily

06

What researchers measure

Primary outcomes

  1. Change from Baseline to Week 4 in Attention Deficit Disorder Investigator Symptom Rating Scale (AISRS) total score

    Time frame: Baseline to Week 4

Secondary outcomes

  1. Change from Baseline to Week 4 in Clinical Global Impression- Severity (CGI-S) scale score

    Time frame: Baseline to Week 4

  2. Incidence of treatment-emergent adverse events

    Time frame: Up to 6 weeks

07

Study locations

28 of 28 sites recruiting
  • Alkermes Investigational Site
    Little Rock, Arkansas 72211, United States
    Recruiting
  • Alkermes Investigational Site
    Chino, California 91710, United States
    Recruiting
  • Alkermes Investigator Site
    Chino, California 91710, United States
    Recruiting
  • Alkermes Investigational Site
    Clermont, Florida 34711, United States
    Recruiting
  • Alkermes Investigational Site
    Jacksonville, Florida 32256, United States
    Recruiting
  • Alkermes Investigational Site
    Lakeland, Florida 33803, United States
    Recruiting
  • Alkermes Investigational Site
    Largo, Florida 33777, United States
    Recruiting
  • Alkermes Investigational Site
    Maitland, Florida 32751, United States
    Recruiting
  • Alkermes Investigator Site
    Maitland, Florida 32751, United States
    Recruiting
  • Alkermes Investigational Site
    Maitland, Florida 98007, United States
    Recruiting
  • Alkermes Investigational Site
    Orange City, Florida 32763, United States
    Recruiting
  • Alkermes Investigational Site
    Orlando, Florida 32801, United States
    Recruiting
  • Alkermes Investigational Site
    Tampa, Florida 33634, United States
    Recruiting
  • Alkermes Investigational Site
    Decatur, Georgia 30030, United States
    Recruiting
  • Alkermes Investigational Site
    Foxborough, Massachusetts 02035, United States
    Recruiting
  • Alkermes Investigational Site
    Watertown, Massachusetts 02472, United States
    Recruiting
  • Alkermes Investigational Site
    Detroit, Michigan 48203, United States
    Recruiting
  • Alkermes Investigational Site
    Lincoln, Nebraska 68526, United States
    Recruiting
  • Alkermes Investigational Site
    Las Vegas, Nevada 89119, United States
    Recruiting
  • Alkermes Investigational Site
    Las Vegas, Nevada 89128, United States
    Recruiting
  • Alkermes Investigational Site
    North Canton, Ohio 44720, United States
    Recruiting
  • Alkermes Investigational Site
    East Providence, Rhode Island 02914, United States
    Recruiting
  • Alkermes Investigational Site
    North Charleston, South Carolina 29405, United States
    Recruiting
  • Alkermes Investigational Site
    Memphis, Tennessee 38119, United States
    Recruiting
  • Alkermes Investigational Site
    Austin, Texas 78737, United States
    Recruiting
  • Alkermes Investigational Site
    Austin, Texas 78759, United States
    Recruiting
  • Alkermes Investigational Site
    The Woodlands, Texas 77381, United States
    Recruiting
  • Alkermes Investigational Site
    Bellevue, Washington 98007, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jul 2027, 11 months after the start.

Of 24 industry-sponsored phase 2 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's planned 11 months is close to that.

Counting every sponsor, half of 40 studies reached it within 15 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2026
First posted
Aug 10, 2026
StartActual
Aug 10, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
27 sites added, 1 site removed
Show 27 added (27 United States)
  • Alkermes Investigational Site · Little Rock, United States
  • Alkermes Investigational Site · Chino, United States
  • Alkermes Investigational Site · Clermont, United States
  • Alkermes Investigational Site · Jacksonville, United States
  • Alkermes Investigational Site · Lakeland, United States
  • Alkermes Investigational Site · Largo, United States
  • Alkermes Investigational Site · Maitland, United States
  • Alkermes Investigational Site · Maitland, United States
  • Alkermes Investigational Site · Orlando, United States
  • Alkermes Investigational Site · Tampa, United States
  • Alkermes Investigational Site · Decatur, United States
  • Alkermes Investigational Site · Memphis, United States
  • Alkermes Investigational Site · North Canton, United States
  • Alkermes Investigational Site · East Providence, United States
  • Alkermes Investigational Site · North Charleston, United States
  • Alkermes Investigational Site · Austin, United States
  • Alkermes Investigational Site · Bellevue, United States
  • Alkermes Investigational Site · Orange City, United States
  • Alkermes Investigational Site · Foxborough, United States
  • Alkermes Investigational Site · Watertown, United States
  • Alkermes Investigational Site · Detroit, United States
  • Alkermes Investigational Site · Lincoln, United States
  • Alkermes Investigational Site · Las Vegas, United States
  • Alkermes Investigational Site · Las Vegas, United States
  • Alkermes Investigational Site · Austin, United States
  • Alkermes Investigational Site · The Woodlands, United States
  • Alkermes Investigational Site · Memphis, United States
Show 1 removed
  • Alkermes Investigational Site · Memphis, United States
across 3 updates, Oct 7, 2026 – Nov 18, 2026
Show all 3 updates
  1. Nov 18, 2026
    1 site added, 1 site removed
    Show site
    • Alkermes Investigational Site · Memphis, United States
    Show 1 removed
    • Alkermes Investigational Site · Memphis, United States
    + 1 other change: verification date
  2. Oct 29, 2026
    9 sites added
    Show 9 added (9 United States)
    • Alkermes Investigational Site · Orange City, United States
    • Alkermes Investigational Site · Foxborough, United States
    • Alkermes Investigational Site · Watertown, United States
    • Alkermes Investigational Site · Detroit, United States
    • Alkermes Investigational Site · Lincoln, United States
    • Alkermes Investigational Site · Las Vegas, United States
    • Alkermes Investigational Site · Las Vegas, United States
    • Alkermes Investigational Site · Austin, United States
    • Alkermes Investigational Site · The Woodlands, United States
  3. Oct 7, 2026
    17 sites added
    Show 17 added (17 United States)
    • Alkermes Investigational Site · Little Rock, United States
    • Alkermes Investigational Site · Chino, United States
    • Alkermes Investigational Site · Clermont, United States
    • Alkermes Investigational Site · Jacksonville, United States
    • Alkermes Investigational Site · Lakeland, United States
    • Alkermes Investigational Site · Largo, United States
    • Alkermes Investigational Site · Maitland, United States
    • Alkermes Investigational Site · Maitland, United States
    • Alkermes Investigational Site · Orlando, United States
    • Alkermes Investigational Site · Tampa, United States
    • Alkermes Investigational Site · Decatur, United States
    • Alkermes Investigational Site · Memphis, United States
    • Alkermes Investigational Site · North Canton, United States
    • Alkermes Investigational Site · East Providence, United States
    • Alkermes Investigational Site · North Charleston, United States
    • Alkermes Investigational Site · Austin, United States
    • Alkermes Investigational Site · Bellevue, United States
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07755410
Lead sponsor
Alkermes, Inc.
Responsible party
Sponsor
First posted
Aug 10, 2026
Start date
Aug 10, 2026
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Global Clinical Services
Contact
clinicaltrials@alkermes.com
888-235-8008 (US Only)
Global Clinical Services
Contact
clinicaltrials@alkermes.com
571-599-2702 (Global)
Medical Director, MD
study director · Alkermes, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion